JP2010520263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520263A5 JP2010520263A5 JP2009552214A JP2009552214A JP2010520263A5 JP 2010520263 A5 JP2010520263 A5 JP 2010520263A5 JP 2009552214 A JP2009552214 A JP 2009552214A JP 2009552214 A JP2009552214 A JP 2009552214A JP 2010520263 A5 JP2010520263 A5 JP 2010520263A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- fluoro
- substituted
- nervous system
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001153 fluoro group Chemical group F* 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 208000012902 Nervous system disease Diseases 0.000 claims 12
- 208000015114 central nervous system disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010015037 epilepsy Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 206010010904 Convulsion Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 239000012442 inert solvent Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 239000002585 base Substances 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
- -1 ethyloxy Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000002920 convulsive effect Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000012025 fluorinating agent Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000005809 status epilepticus Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000022540 Consciousness disease Diseases 0.000 claims 1
- 206010012225 Delirium tremens Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000037158 Partial Epilepsies Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000006246 alcohol withdrawal delirium Diseases 0.000 claims 1
- 208000022780 alcohol-induced mental disease Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 238000005799 fluoromethylation reaction Methods 0.000 claims 1
- 201000007186 focal epilepsy Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000003227 neuromodulating effect Effects 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000011426 transformation method Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103654 | 2007-03-07 | ||
| PCT/EP2007/052442 WO2007104783A2 (en) | 2006-03-15 | 2007-03-15 | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators |
| EP07116401 | 2007-09-14 | ||
| PCT/EP2008/052766 WO2008107479A1 (en) | 2007-03-07 | 2008-03-07 | 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520263A JP2010520263A (ja) | 2010-06-10 |
| JP2010520263A5 true JP2010520263A5 (cg-RX-API-DMAC7.html) | 2011-04-21 |
Family
ID=39430637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552214A Pending JP2010520263A (ja) | 2007-03-07 | 2008-03-07 | ３−シアノ−４−（４−フェニル−ピペリジン−１−イル）−ピリジン−２−オン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100063092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2134701A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010520263A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090125813A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101679349A (cg-RX-API-DMAC7.html) |
| AR (1) | AR065622A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008223794A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0808666A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2680120A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA017280B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL200328A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009009423A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200900391A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008107479A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| DK2137162T3 (en) | 2007-03-15 | 2018-11-26 | Novartis Ag | Organic compounds and their applications |
| RS51660B (sr) | 2007-09-14 | 2011-10-31 | Ortho-Mcneil-Janssen Pharmaceuticals Inc. | 1`,3`-disupstituisani-4-fenil-3,4,5,6-tetrahidro-2h, 1`h-[1,4`] bipiridinil-2`-oni |
| ATE516272T1 (de) | 2007-09-14 | 2011-07-15 | Ortho Mcneil Janssen Pharm | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one |
| WO2009033703A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| EP2220083B1 (en) | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| EP2344470B1 (en) * | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| KR20120035158A (ko) | 2009-05-12 | 2012-04-13 | 얀센 파마슈티칼즈, 인코포레이티드 | 1,２,４?트리아졸로［４,３?ａ］피리딘 유도체 및 ｍＧｌｕＲ２ 수용체의 양성 알로스테릭 조절자로서의 그의 용도 |
| US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
| JP2013531636A (ja) | 2010-05-26 | 2013-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−オキソ−１，２−ジヒドロピリジン−４−イルボロン酸誘導体 |
| EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CA2814996C (en) | 2010-11-08 | 2019-10-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| PT3421462T (pt) | 2013-06-27 | 2023-06-29 | Pfizer | Compostos heteroaromáticos e a sua utilização como ligandos de d1 de dopamina |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| CN109999033B (zh) | 2014-01-21 | 2022-12-23 | 詹森药业有限公司 | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 |
| HRP20191646T1 (hr) | 2014-01-21 | 2019-12-13 | Janssen Pharmaceutica Nv | Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba |
| CN105153027A (zh) * | 2015-07-21 | 2015-12-16 | 东华大学 | 一种3-氰基-4-羟基-2-吡啶酮类化合物及其制备和应用 |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056990A2 (en) * | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| AU2003262805A1 (en) * | 2002-08-26 | 2004-03-11 | Merck & Co., Inc. | Acetophenone potentiators of metabotropic glutamate receptors |
| CA2527170A1 (en) * | 2003-04-15 | 2004-10-28 | Astrazeneca Ab | Therapeutic compounds |
| UA85576C2 (ru) * | 2004-02-18 | 2009-02-10 | Астразенека Аб | Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата |
| WO2006014918A2 (en) * | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
| CN1993335A (zh) * | 2004-07-30 | 2007-07-04 | 默克公司 | 代谢型谷氨酸受体的二氢茚酮增效剂 |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) * | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
-
2008
- 2008-03-06 TW TW097107950A patent/TW200900391A/zh unknown
- 2008-03-06 AR ARP080100930A patent/AR065622A1/es not_active Application Discontinuation
- 2008-03-07 BR BRPI0808666-4A patent/BRPI0808666A2/pt not_active IP Right Cessation
- 2008-03-07 AU AU2008223794A patent/AU2008223794A1/en not_active Abandoned
- 2008-03-07 CA CA002680120A patent/CA2680120A1/en not_active Abandoned
- 2008-03-07 WO PCT/EP2008/052766 patent/WO2008107479A1/en not_active Ceased
- 2008-03-07 JP JP2009552214A patent/JP2010520263A/ja active Pending
- 2008-03-07 EA EA200901159A patent/EA017280B1/ru not_active IP Right Cessation
- 2008-03-07 EP EP08717513A patent/EP2134701A1/en not_active Withdrawn
- 2008-03-07 US US12/529,632 patent/US20100063092A1/en not_active Abandoned
- 2008-03-07 CN CN200880007307A patent/CN101679349A/zh active Pending
- 2008-03-07 MX MX2009009423A patent/MX2009009423A/es active IP Right Grant
- 2008-03-07 KR KR1020097020925A patent/KR20090125813A/ko not_active Ceased
-
2009
- 2009-08-11 IL IL200328A patent/IL200328A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520263A5 (cg-RX-API-DMAC7.html) | ||
| JP2010520264A5 (cg-RX-API-DMAC7.html) | ||
| JP2010520265A5 (cg-RX-API-DMAC7.html) | ||
| JP2012510437A5 (cg-RX-API-DMAC7.html) | ||
| US10858353B2 (en) | Intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
| TW201609696A (zh) | 用於製備３－（３－氯－１ｈ－吡唑－１－基）吡啶的方法（三） | |
| KR20240164495A (ko) | Nlrp3의 억제제 | |
| EP2099763B1 (en) | 2-aminoquinolines as 5-ht(5a) receptor antagonists | |
| JP2010540483A (ja) | ５−ｈｔ５ａ受容体アンタゴニストとしてのキノリン誘導体 | |
| KR20190013553A (ko) | 아미노피리미딘 유도체의 개선된 제조방법 | |
| JP2011517443A5 (cg-RX-API-DMAC7.html) | ||
| US7989628B2 (en) | 2-aminoquinolines | |
| WO2011132048A1 (en) | Heteroaryl compounds as pde10a inhibitors | |
| JP2013529672A (ja) | キノリン−３−カルボキサミドの製造方法 | |
| CN87100298A (zh) | 制备喹啉-3-羧酸抗菌剂的改进方法 | |
| US7994324B2 (en) | 2-aminoquinoline derivatives | |
| JP7284172B2 (ja) | ピリミジニル－４－アミノピラゾール化合物の調製方法 | |
| WO2004005276A1 (ja) | １，３−ベンゾジオキソール−２−スピロシクロアルカン誘導体の製造法 | |
| EP1614672B1 (en) | An amino alcohol ligand and its use in preparation of chiral proparglic tertiary alkohols and tertiary amines via enantioselective additon reaction | |
| WO2012119507A1 (zh) | 3-巯基丙酸酯的制备 | |
| EP1572657B1 (en) | Processes for preparing quinolonecarboxylate derivatives | |
| TW201538487A (zh) | 吡唑化合物之製造方法 | |
| JP5368567B2 (ja) | ５−置換ベンゾオキサジン | |
| SK287721B6 (en) | Process for producing quinoline carboxyaldehyde derivative and intermediate thereof | |
| BR112020001396B1 (pt) | Intermediários úteis na síntese de derivados de aminopirimidina, processo para preparar os mesmos e processo para preparar derivados de aminopirimidina usando os mesmos |